PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
This study aimed to establish the PBPK models of venlafaxine and its active metabolite related to CYP2D6 genetic polymorphism and to predict drug-drug interactions (DDIs) with clarithromycin and paroxetine in different CYP2D6 genotypes. Clinical pharmacogenomic data for venlafaxine and desvenlafaxine were collected to build the PBPK model. Physicochemical and absorption, distribution, metabolism, and excretion (ADME) characteristics of respective compounds were obtained from previously reported data, predicted by the PK-Sim® software, or optimized to capture the plasma concentration-time profiles. Model evaluation was per...
Source: Archives of Pharmacal Research - April 25, 2024 Category: Drugs & Pharmacology Authors: Chang-Keun Cho Pureum Kang Choon-Gon Jang Seok-Yong Lee Yun Jeong Lee Jung-Woo Bae Chang-Ik Choi Source Type: research
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Arch Pharm Res. 2024 Apr 17. doi: 10.1007/s12272-024-01494-1. Online ahead of print.ABSTRACTThe molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical tria...
Source: Archives of Pharmacal Research - April 17, 2024 Category: Drugs & Pharmacology Authors: Yajun Liu Chenyao Li Hongwei Liu Shutao Tan Source Type: research
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Arch Pharm Res. 2024 Apr 17. doi: 10.1007/s12272-024-01494-1. Online ahead of print.ABSTRACTThe molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical tria...
Source: Archives of Pharmacal Research - April 17, 2024 Category: Drugs & Pharmacology Authors: Yajun Liu Chenyao Li Hongwei Liu Shutao Tan Source Type: research
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Arch Pharm Res. 2024 Apr 17. doi: 10.1007/s12272-024-01494-1. Online ahead of print.ABSTRACTThe molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical tria...
Source: Archives of Pharmacal Research - April 17, 2024 Category: Drugs & Pharmacology Authors: Yajun Liu Chenyao Li Hongwei Liu Shutao Tan Source Type: research
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Arch Pharm Res. 2024 Apr 17. doi: 10.1007/s12272-024-01494-1. Online ahead of print.ABSTRACTThe molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical tria...
Source: Archives of Pharmacal Research - April 17, 2024 Category: Drugs & Pharmacology Authors: Yajun Liu Chenyao Li Hongwei Liu Shutao Tan Source Type: research
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research
TNF receptor 2 knockout mouse had reduced lung cancer growth and schizophrenia-like behavior through a decrease in TrkB-dependent BDNF level
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01487-0. Online ahead of print.ABSTRACTThe relationship between schizophrenia (SCZ) and cancer development remains controversial. Based on the disease-gene association platform, it has been revealed that tumor necrosis factor receptor (TNFR) could be an important mediatory factor in both cancer and SCZ development. TNF-α also increases the expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) in the development of SCZ and tumor, but the role of TNFR in mediating the association between the two diseases remains unclear. We studied...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: In Jun Yeo Ji Eun Yu Sung-Hyun Kim Dae Hwan Kim Miran Jo Dong Ju Son Jaesuk Yun Sang-Bae Han Jin Tae Hong Source Type: research
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research
TNF receptor 2 knockout mouse had reduced lung cancer growth and schizophrenia-like behavior through a decrease in TrkB-dependent BDNF level
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01487-0. Online ahead of print.ABSTRACTThe relationship between schizophrenia (SCZ) and cancer development remains controversial. Based on the disease-gene association platform, it has been revealed that tumor necrosis factor receptor (TNFR) could be an important mediatory factor in both cancer and SCZ development. TNF-α also increases the expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) in the development of SCZ and tumor, but the role of TNFR in mediating the association between the two diseases remains unclear. We studied...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: In Jun Yeo Ji Eun Yu Sung-Hyun Kim Dae Hwan Kim Miran Jo Dong Ju Son Jaesuk Yun Sang-Bae Han Jin Tae Hong Source Type: research
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research
TNF receptor 2 knockout mouse had reduced lung cancer growth and schizophrenia-like behavior through a decrease in TrkB-dependent BDNF level
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01487-0. Online ahead of print.ABSTRACTThe relationship between schizophrenia (SCZ) and cancer development remains controversial. Based on the disease-gene association platform, it has been revealed that tumor necrosis factor receptor (TNFR) could be an important mediatory factor in both cancer and SCZ development. TNF-α also increases the expression of brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) in the development of SCZ and tumor, but the role of TNFR in mediating the association between the two diseases remains unclear. We studied...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: In Jun Yeo Ji Eun Yu Sung-Hyun Kim Dae Hwan Kim Miran Jo Dong Ju Son Jaesuk Yun Sang-Bae Han Jin Tae Hong Source Type: research
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Arch Pharm Res. 2024 Apr 9. doi: 10.1007/s12272-024-01493-2. Online ahead of print.ABSTRACTSarcopenia is a multifactorial condition characterized by loss of muscle mass. It poses significant health risks in older adults worldwide. Both pharmacological and non-pharmacological approaches are reported to address this disease. Certain dietary patterns, such as adequate energy intake and essential amino acids, have shown positive outcomes in preserving muscle function. Various medications, including myostatin inhibitors, growth hormones, and activin type II receptor inhibitors, have been evaluated for their effectiveness in man...
Source: Archives of Pharmacal Research - April 9, 2024 Category: Drugs & Pharmacology Authors: Youle Zheng Jin Feng Yixin Yu Min Ling Xu Wang Source Type: research
